Written by Seth Walsh-Blackmore
Spoon Feed
1) DOAC: 4F-PCC
2) VKA: 4F-PCC + vitamin K
3) DTI: if dabigatran, idarucizumab; can try 4F-PCC
4) Heparin (even LMWH): protamine
No time to bleed, no time to read (a full article)
Direct Oral Anticoagulants (DOAC): Rivaroxaban, Apixaban, Edoxaban, and Betrixiban
- Monitored by Anti-Xa level.
- Four-factor prothrombin complex concentrate (PCC) is used off-label for DOAC reversal, with typical doses of 25–50 U/kg reported in small observational studies.
- Andexanet alfa is a specific reversal agent for apixaban and rivaroxaban. It has been withdrawn from the United States market due to safety concerns.
Vitamin K antagonists: Warfarin, Phenprocoumon, Acenocoumarol
- Monitored by PT/INR.
- The most effective reversal regimen is 25–50 IU/kg four-factor PCC combined with 5–10 mg intravenous vitamin K.
- Three-factor PCC, fresh frozen plasma (FFP), and oral vitamin K are less effective and carry a similar thrombotic risk.
- Recombinant factor VII and activated PCC are off-label for reversal and may carry a higher thrombotic risk.
- Fixed dosing regimens of 750–3000 IU (depending on the site of bleeding) for 4-factor PCC are off-label but may improve time to therapy and reduce total dose without compromising efficacy.
Direct Thrombin Inhibitors: Dabigatran, Argatroban, Bivalirudin
- All agents usually prolong aPTT. Activated clotting time (ACT) can be used for bivalirudin and argatroban.
- Dabigatran is the only oral agent in this class and has a specific antidote, idarucizumab. The dose is a 2.5 g IV bolus, with a second 2.5 g dose if necessary. It takes effect within five minutes. Anticoagulant rebound may occur approximately 24 hours.
- Argatroban and bivalirudin are IV agents without specific reversal agents. Their half-lives are less than one hour unless there is advanced liver disease (argatroban) or renal disease (bivalirudin). Dialysis can remove bivalirudin but is ineffective for argatroban. Off-label use of 4-factor PCC and cryoprecipitate has been reported for both agents in cases of severe bleeding.
Heparin Agents: Unfractioned Heparin, Enoxaparin, Dalteparin
- Heparin is monitored by aPTT and ACT. Enoxaparin and dalteparin are monitored by Anti-Xa level.
- Protamine sulfate is approved only for the reversal of unfractionated heparin and dosed at 1mg protamine per 100 IU heparin. It can also be titrated to ACT.
- Although off-label, protamine is partially effective for reversing enoxaparin at a recommended dose of 1 mg protamine per 1 mg enoxaparin if the last dose was administered less than eight hours prior. A rebound effect may occur.
- Excess circulating protamine can induce coagulopathy, emphasizing the importance of appropriate dosing ratios. Some experts recommend starting at lower doses and titrating upward.
- Protamine should be administered slowly over 5–10 minutes or longer to minimize the risk of protamine reactions.
How will this change my practice?
I recommend reading the full article for its comprehensive tables, diagrams, and details. I do not believe andexanet alfa is justified, given its cost and safety profile compared to four-factor PCC. Four-factor PCC appears to be a reasonable option for agents without a specific antidote, including DOACs, and should be prioritized for immediate availability. If a patient’s weight is unknown, use a fixed-dose regimen.
Source
Antidotes for Anticoagulation Reversal. N Engl J Med. 2026 Jun 11;394(22):2235-2254. doi: 10.1056/NEJMra2506021. PMID: 42269153.
